循环无细胞DNA检测及在肝病中的研究应用
Detection and Application of Circulating-Free Cell DNA in Hepatopathy
DOI: 10.12677/MD.2013.31003, PDF, HTML, XML, 下载: 3,334  浏览: 11,556 
作者: 陈恳, 张弘*：南通大学附属医院消化内科，南通
关键词: 循环无细胞DNA；检测；肝病；Circulating-Free Cell DNA; Detection; Hepatopathy
摘要: 循环无细胞DNA是一种无细胞状态的胞外DNA，广泛存在于人体体液中。近年来，对循环无细胞DNA的研究逐渐受到人们的重视，越来越多的研究将循环无细胞DNA与临床疾病的关系联系起来。现将近年来有关循环无细胞DNA检测的研究及循环无细胞DNA在肝病中的研究进展作一综述。 Circulating-free cell DNA (cfDNA) is a class of extrocellular DNA without cellular structure, presenting ex-tensively in human body fluids. Recently, cfDNA has gradully received more attention, and extensive studies have in-dicated the relationship between cfDNA and clinical diseases. Here, we review the researches about detection of cfDNA and the research progress about cfDNA in liver disease in recent years.
文章引用：陈恳, 张弘. 循环无细胞DNA检测及在肝病中的研究应用[J]. 医学诊断, 2013, 3(1): 10-14. http://dx.doi.org/10.12677/MD.2013.31003

参考文献

[1] P. Mandel, P. Metais. Les acides nucleiques du plasma sanguin chez 1’ Homme. Comptes Rendus de l’Académie des Sciences Paris, 1948, 142(3): 241-243.
[2] S. A. Leon, B. Shapiro, D. M. Sklaroff, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Re- search, 1977, 37(3): 646-650.
[3] K. W. Lo, Y. M. D. Lo, S. F. Leung, et al. Analysis of cell-free Epstein-Barr virus-associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clinical Chemistry, 1999, 45(8): 1292-1294.
[4] M. S. Kopreski, F. A. Benko, L. W. Kwak, et al. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clinical Cancer Research, 1999, 5(8): 1961-1965.
[5] 杨波, 吴小华, 孙东霞等. 卵巢上皮性癌患者血清无细胞DNA的检测及临床意义[J]. 肿瘤, 2008, 28(4): 334-337.
[6] R. R Jing, J.-H. Zhu, H.-M. Wang, et al. A sensitive method to quantify human circulating free DNA in blood: Relevance to myocardial infarction screening. Clinical Biochemistry, 2011, 44(13): 1074-1079.
[7] B. G. Wang, H. Y. Huang, Y. C. Chen, et al. Increased plasma DNA integrity in cancer patients. Cancer Research, 2003, 63(14): 3966-3968.
[8] S. Holdenrieder, A. Burges, O. Reich, et al. DNA integrity in plasma and serum of patients with malignant and benign disease. Annals of the New York Academy of Sciences, 2008, 1137: 162- 170.
[9] M. S. Kopreski, F. A. Benko, D. J. Borys, et al. Somatic muta- tion screening: Identification of individuals harboring K-ras mutations with the use of plasma DNA. National Cancer Insti- tute, 2000, 92: 918-923.
[10] Z. M. Shao, J. Wu, Z. Z. Shen, et al. p53 mutation in plasma DNA and its prognostic value in breast cancer patients. Clinical Cancer Research, 2001, 7(8): 2222-2227.
[11] R. Von knobloch, A. Hegele, H. Brandt, et al. Serum DNA and urine DNA alterations of urinary transitional cell bladder carci- noma detected by fluorescent microsatellite analysis. Interna- tional Journal of Cancer, 2001, 94(1): 67-72.
[12] C. Goessl, H. Krause, M. Muller, et al. Fluorescent methylation- specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Research, 2000, 60(21): 5941-5945.
[13] I. J. Marin, M. Poljak, K. Seme, et al. Comparative evaluation of three commercial assays for quantitative measurement of hepati- tis B virus DNA in serum samples. Hepatogastroenterology, 2002, 49(47): 1390-1394.
[14] S. K. Ho, T. M. Chan. An overview of assays for serum HBV DNA. Clinical Laboratory, 2000, 46(11-12): 609-614.
[15] J. Saldanha. Validation and standardization of nucleic acid am- plification technology (NAT) assays for the detection of viral contamination of blood and blood products. Journal of Clinical Virology, 2001, 20(1-2): 7-13.
[16] 傅占江, 范丽娜, 王沛等. 枝状DNA 信号放大与纸层析杂交检测方法的建立[J]. 中华微生物学和免疫学杂志, 2002, 22(4): 468-469.
[17] K. J. Livak, S. J. Flood, J. Marmaro, et al. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe sys- tem useful for detecting PCR product and nucleic acid hybridi- zation. PCR Methods and Applications, 1995, 4(6): 357-362.
[18] J. Hayashi, Y. Kawakami, A. Nabeshima, et al. Comparison of HCV RNA levels by branched DNA probe assay and by com- petitive polymerase chain reaction to predict effectiveness of in- terferon treatment for patients with chronic hepatitis C virus. Digestive Diseases and Sciences, 1998, 43(2): 384-391.
[19] M. L. Collins, B. Irvine, D. Tyner, et al. A branched DNA signal amplification assay for quantification of nucleic acid targets be- low 100 molecules/ml. Nucleic Acids Research, 1997, 25(15): 2979-2984.
[20] 罗迪贤, 李凯, 何淑雅等. Alu家族及其生物学意义[J]. 遗传, 2005, 27(2): 284-288.
[21] L. Just, M. Timmer, J. Tinius, et al. Identification of human cells in brain xenografts and in neural co-cultures of rat by in situ hy- bridisation with Alu probe. Journal of Neuroscience Methods, 2003, 126(1): 69-77.
[22] G. J. Nuovo, P. MacConnell. Detection of human papilloma virus DNA in formalin-fixed tissues by in situ hybridization after amplification by polymerase chain reaction. American Journal of Pathology, 1991, 139: 847-854.
[23] 任宁, 钦伦秀, 屠红等. 肝细胞癌病人血浆DNA定量分析及其临床意义[J]. 复旦学报, 2005, 32(2): 134-138.
[24] N. Ren, L. X. Qin, H. Tu, et al. The prognostic value of circu- lating plasma DNA level and its allelic imbalance on chromo- some 8p in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2006, 132(6): 399-407.
[25] N. Ren, Q. H. Ye, L. X. Qin, et al. Circulating DNA level is ne- gatively associated with the long-term survival of hepatocellular carcinoma patients. World Journal of Gastroenterology, 2006, 12(24): 3911-3914.
[26] Y. Tokuhisa, N. Lizuka, I. Sakaida,et al. Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. British Journal of Cancer, 2000, 97(10): 1399-1403.